TAO Synergies (TAOX) Stock Price

Synaptogenix, Inc. develops Bryostatin-1, a drug candidate derived from a marine invertebrate, targeting Alzheimer's disease, Fragile X Syndrome, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company focuses on therapeutics for neurodegenerative diseases and developmental disorders, leveraging Bryostatin-1 as a Protein Kinase C Epsilon activator. Products are sold to healthcare providers and research institutions for clinical use and further development. The firm's primary revenue comes from licensing agreements and partnerships with biopharmaceutical companies seeking to advance Bryostatin-1 applications. Synaptogenix, Inc. evaluates Bryostatin for multiple conditions including Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease. The company's platform drug is used in clinical trials and therapeutic development, with key buyers being biopharmaceutical firms and research organizations. Revenue streams include product development partnerships and licensing fees from companies utilizing Bryostatin-1 for neurodegenerative disease treatments. The business model centers on Bryostatin-1 as a core therapeutic, with applications across Alzheimer's, Fragile X, and other conditions. The company's focus on neurodegenerative diseases drives partnerships with biopharmaceutical companies, generating revenue through licensing and development agreements. Sales are directed toward healthcare providers and research institutions for clinical applications.